Phase 3 Oncology Compounds main Article

Breakthrough Science Franchise

Breakthrough Science Franchise

The investigational Breakthrough Science Franchise of the Daiichi Sankyo Cancer Enterprise aims to leverage our world-class science to research and develop innovative therapies with new technologies through internal discovery and active partnership.

Pexidartinib: CSF-1R Inhibitor


Pexidartinib (formerly known as PLX3397) is an investigational oral selective inhibitor of CSF-1R in phase 3 development for tenosynovial giant cell tumor (TGCT), which includes pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS). TGCT is a rare, usually non-cancerous tumor that affects the synovium-lined joints, bursae, and tendon sheaths. Pexidartinib has been granted Orphan Drug Designation and Breakthrough Therapy Designation by the FDA for the treatment of TGCT. It also has received Orphan Drug Designation from EMA for the treatment of TGCT.


Patritumab: HER3 Inhibitor


Patritumab is an investigational fully human HER3-targeting monoclonal antibody in phase 2 clinical development as part of a combination therapy for recurrent or metastatic head and neck cancer. For more information about this phase 2 study, visit

These are investigational agents and have not been approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Safety and efficacy have not been established.



Oncology more stories content

More Stories

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer.

read more ...